Top Markets
#1 0G 0G +40.67%
#2 Merlin's Seal BTC Merlin's Seal BTC +37.95%
#3 StonkBroker StonkBroker +34.05%
#4 Useless Coin Useless Coin +33.72%
#5 SAFEcoin SAFEcoin +30.41%
#6 Dogs Dogs +24.40%
#7 Pons Pons +23.19%
#8 rsERG rsERG +22.64%
#9 Zora Zora +22.63%
#10 ICON ICON +21.32%
Coin of the day
0G 0G
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Impact Therap-b Impact Therap-b

Impact Therap-b

7630
Rangering i aksjer #13196
IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and... IMPACT Therapeutics, a biotechnology firm, specializes in the discovery and advancement of precision anti-cancer treatments rooted in synthetic lethality, operating across China and international markets. The company's primary offering, Senaparib (IMP4297), is a PARP1/2 inhibitor currently deployed as a first-line maintenance therapy for ovarian cancer. Beyond this, Impact Therapeutics maintains a robust pipeline of investigational drugs. This includes IMP1734, a next-generation PARP1 selective inhibitor undergoing Phase I/II trials as a standalone treatment for advanced solid tumors. Another promising candidate is IMP9064, an ATR kinase selective inhibitor, also in Phase I/II clinical studies for advanced solid tumors as a monotherapy. IMP1707, a PARP1 selective inhibitor capable of penetrating the central nervous system, is in Phase I development for homologous recombination repair-deficient tumors. Additionally, IMP7068, an advanced WEE1 inhibitor, is progressing through Phase I/II clinical trials for various advanced solid tumors. Furthermore, a range of other compounds, namely IMP22, IMP25, IMP08, IMP13, IMP10, IMP27, and IMP32, are in the preclinical development phase. The company, established in 2009, is headquartered in Shanghai, China.
Aksjekurs
$1.85
Markedsverdi
$510.85M
Endring (1 dag)
-7.37%
Endring (1 år)
-
Land
CN
Handel Impact Therap-b (7630)

Kategori

Healthcare
Utbytteavkastning for Impact Therap-b (7630)
Impact Therap-b (aksjesymbol: 7630) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Impact Therap-b (7630) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
Selskap Utbytteavkastning Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
0.57%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
2.01%
US
AbbVie Inc. AbbVie Inc.
AbbVie Inc.
ABBV.US
2.74%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
2.69%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
2.47%
US